Addressing the Lp(a) hypothesis: will lowering Lp(a) decrease the risk of cardiovascular events?
- 17 March 2026
- journal article
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 23 (5) , 293-295
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Lipoprotein(a)-lowering therapies: a promising futureEuropean Heart Journal, 2026
- Between Scylla and Charybdis – Enigmatic role of lipoprotein(a) in atherosclerotic cardiovascular disease and type 2 diabetes mellitusDiabetes Research and Clinical Practice, 2025
- The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targetsCurrent Opinion in Lipidology, 2025
- Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory BiomarkersJAMA Cardiology, 2025
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statementEuropean Heart Journal, 2022
- Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2020
- Lipoprotein(a) Reduction in Persons with Cardiovascular DiseaseNew England Journal of Medicine, 2020
- Kringle IV Type 2, Not Low Lipoprotein(a), as a Cause of Diabetes: A Novel Genetic Approach Using SNPs Associated Selectively with Lipoprotein(a) Concentrations or with Kringle IV Type 2 RepeatsClinical Chemistry, 2017
- Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary DiseaseNew England Journal of Medicine, 2009
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial InfarctionJAMA, 2009